Propanc Biopharma, Inc. Common Stock (PPCB) - Total Liabilities

Latest as of March 2026: $4.51 Million USD

Based on the latest financial reports, Propanc Biopharma, Inc. Common Stock (PPCB) has total liabilities worth $4.51 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Propanc Biopharma, Inc. Common Stock - Total Liabilities Trend (2010–2025)

This chart illustrates how Propanc Biopharma, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. See PPCB working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Propanc Biopharma, Inc. Common Stock Competitors by Total Liabilities

The table below lists competitors of Propanc Biopharma, Inc. Common Stock ranked by their total liabilities.

Company	Country	Total Liabilities
Bounty Oil & Gas NL AU:BUY	Australia	AU$4.44 Million
Angel Wing Metals Inc V:AWM	Canada	CA$261.12K
Kridhan Infra Limited NSE:KRIDHANINF	India	Rs3.04 Billion
Xpon Technologies Group Ltd AU:XPN	Australia	AU$16.05 Million
SKRR Exploration Inc V:SKRR	Canada	CA$11.55K
Iljeong Ind KO:008500	Korea	₩19.97 Billion
Fon SE WAR:FON	Poland	zł4.33 Million
Kmc Properties ASA OL:KMCP	Norway	Nkr10.54 Billion

Liability Composition Analysis (2010–2025)

This chart breaks down Propanc Biopharma, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PPCB market cap.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.37	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.46	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.31	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Propanc Biopharma, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Propanc Biopharma, Inc. Common Stock (2010–2025)

The table below shows the annual total liabilities of Propanc Biopharma, Inc. Common Stock from 2010 to 2025.

Year	Total Liabilities	Change
2025-06-30	$5.73 Million	+48.66%
2024-06-30	$3.85 Million	+21.21%
2023-06-30	$3.18 Million	+2.33%
2022-06-30	$3.11 Million	+0.80%
2021-06-30	$3.08 Million	-17.63%
2020-06-30	$3.74 Million	-15.06%
2019-06-30	$4.40 Million	-35.47%
2018-06-30	$6.82 Million	+23.24%
2017-06-30	$5.54 Million	+88.04%
2016-06-30	$2.94 Million	-20.00%
2015-06-30	$3.68 Million	+141.82%
2014-06-30	$1.52 Million	+91.64%
2013-06-30	$794.22K	+35.95%
2012-06-30	$584.19K	+90.38%
2011-06-30	$306.85K	+32.97%
2010-06-30	$230.76K	--

About Propanc Biopharma, Inc. Common Stock

NASDAQ:PPCB USA Biotechnology

Market Cap

$3.90 Million

Market Cap Rank

#29418 Global

#5942 in USA

Share Price

$1.71

Change (1 day)

-11.40%

52-Week Range

$0.07 - $2.43

All Time High

$2.43